bluebird bio Inc (BLUE)

128.75
NASDAQ : Health Care
Prev Close 127.85
Day Low/High 127.00 / 130.50
52 Wk Low/High 37.05 / 136.85
Avg Volume 884.40K
Exchange NASDAQ
Shares Outstanding 45.59M
Market Cap 5.83B
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio To Present Interim Clinical Data From Starbeam Study Of Lenti-DTM Drug Product In Cerebral Adrenoleukodystrophy (CALD) At Child Neurology Society (CNS) 2017 Annual Meeting

Bluebird Bio To Present Interim Clinical Data From Starbeam Study Of Lenti-DTM Drug Product In Cerebral Adrenoleukodystrophy (CALD) At Child Neurology Society (CNS) 2017 Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Bluebird Bio To Present At Investor Conferences In September

Bluebird Bio To Present At Investor Conferences In September

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

This team is playoff-ready and built for the ages.

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

I've cut a few positions and haven't made any notable buys today.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Here's what you need to know now for Tuesday, August 29.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Bluebird Bio To Present At Wedbush PacGrow Healthcare Conference

Bluebird Bio To Present At Wedbush PacGrow Healthcare Conference

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Reports Second Quarter 2017 Financial Results And Recent Operational Progress

Bluebird Bio Reports Second Quarter 2017 Financial Results And Recent Operational Progress

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business...

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an...

Time to Take Profits in Bluebird Bio

Time to Take Profits in Bluebird Bio

This biotech has done well so far this year, but now it's time to lock in some gains.

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an...

Bluebird Bio Announces Topline Interim Clinical Data From Starbeam Study Of Lenti-D™ Drug Product In Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced topline...

Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease (SCD) At European Hematology Association (EHA) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced new data...

Bluebird Bio Announces Early Data From Phase 3 Northstar-2 (HGB-207) Study Of LentiGlobinTM Drug Product At European Hematology Association (EHA) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced early...

Bluebird Bio Appoints Two New Directors to its Board

Bluebird Bio Appoints Two New Directors to its Board

bluebird bio appointed John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to its Board of Directors.

Bluebird Bio Appoints John O. Agwunobi, M.D. And Douglas A. Melton, Ph.D. To Board Of Directors

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it...

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Gold Action Highlights Event Risk

Comey's Senate testimony looms.

Bluebird Bio Stock Upgraded at BMO

Bluebird Bio Stock Upgraded at BMO

Upcoming data readouts throughout the remainder of this year will 'provide investors with multiple opportunities for upside across TDT, SCD and myeloma,' BMO analyst Matt Luchini noted.

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel.

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

100% response rate with zero relapses are the latest update from Bluebird's BB2121 study in multiple myeloma patients.

Bluebird Bio And Celgene Corporation Announce Updated Clinical Results From Ongoing First-in-Human Multicenter Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

bluebird bio, Inc. (NASDAQ:BLUE), and Celgene Corporation (NASDAQ:CELG) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell...

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.

Bluebird Bio To Present At Two Investor Conferences In June

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Announces Collaboration With Duke University's Robert J. Margolis, MD, Center For Health Policy On Value-Based Payment Framework For Gene Therapy

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will...

TheStreet Quant Rating: D+ (Sell)